Randomized Study of Bevacizumab vs Ranibizumab for Age-Related Macular Degeneration: Inappropriate Conclusions

American Journal of Ophthalmology

Volumn 149, Issue 5, 2010, Pages 867-

  Messori, Andrea ^a   Fadda, Valeria ^a   Trippoli, Sabrina ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; HUMAN; LETTER; OUTCOME ASSESSMENT; PHYSICIAN; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; SAMPLE SIZE; TREATMENT RESPONSE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; HUMANS; INJECTIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY; WET MACULAR DEGENERATION;

EID: 77950846627     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2009.12.039     Document Type: Letter

References (1)

1. Subramanian M.L., Ness S., Abedi G., et al. Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial. Am J Ophthalmol 148 6 (2009) 875-882